Titre :

Impact of the SARS-CoV-2 pandemic on the health of individuals with intoxication-type metabolic diseases - data from the E-IMD consortium.

Auteur(s) :

Mütze, U. [Auteur]
Gleich, F. [Auteur]
Barić, I. [Auteur]
Baumgartner, M. [Auteur]
Burlina, A. [Auteur]
Chapman, K. A. [Auteur]
Chien, Y. [Auteur]
Cortès-Saladelafont, E. [Auteur]
De Laet, C. [Auteur]
Dobbelaere, Dries [Auteur]
Maladies Rares du Développement : Génétique, Régulation et Protéomique (RADEME) - ULR 7364
Eysken, F. [Auteur]
Gautschi, M. [Auteur]
Santer, R. [Auteur]
Häberle, J. [Auteur]
Joaquín, C. [Auteur]
Karall, D. [Auteur]
Lindner, M. [Auteur]
Lund, A. M. [Auteur]
Mühlhausen, C. [Auteur]
Murphy, E. [Auteur]
Roland, D. [Auteur]
Ruiz Gomez, A. [Auteur]
Skouma, A. [Auteur]
Grünert, S. C. [Auteur]
Wagenmakers, M. [Auteur]
Garbade, S. F. [Auteur]
Kölker, S. [Auteur]
Boy, N. [Auteur]

Titre de la revue :

J Inherit Metab Dis

Nom court de la revue :

J Inherit Metab Dis

Numéro :

46

Pagination :

220-231

Date de publication :

2022-10-23

ISSN :

1573-2665

Mot(s)-clé(s) en anglais :

coronavirus
COVID-19
E-IMD
IMD
intoxication-type inherited metabolic diseases
pandemic
SARS-CoV-2
survey

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The SARS-CoV-2 pandemic challenges healthcare systems worldwide. Within inherited metabolic disorders (IMDs) the vulnerable subgroup of intoxication-type IMDs such as organic acidurias (OA) and urea cycle disorders (UCD) ...
Lire la suite >The SARS-CoV-2 pandemic challenges healthcare systems worldwide. Within inherited metabolic disorders (IMDs) the vulnerable subgroup of intoxication-type IMDs such as organic acidurias (OA) and urea cycle disorders (UCD) show risk for infection-induced morbidity and mortality. This study (observation period February 2020 to December 2021) evaluates impact on medical health care as well as disease course and outcome of SARS-CoV-2 infections in patients with intoxication-type IMDs managed by participants of the European Registry and Network for intoxication type metabolic diseases Consortium (E-IMD). Survey's respondents managing 792 patients (n = 479 pediatric; n = 313 adult) with intoxication-type IMDs (n = 454 OA; n = 338 UCD) in 14 countries reported on 59 (OA: n = 36; UCD: n = 23), SARS-CoV-2 infections (7.4%). Medical services were increasingly requested (95%), mostly alleviated by remote technologies (86%). Problems with medical supply were scarce (5%). Regular follow-up visits were reduced in 41% (range 10%–50%). Most infected individuals (49/59; 83%) showed mild clinical symptoms, while 10 patients (17%; n = 6 OA including four transplanted MMA patients; n = 4 UCD) were hospitalized (metabolic decompensation in 30%). ICU treatment was not reported. Hospitalization rate did not differ for diagnosis or age group (p = 0.778). Survival rate was 100%. Full recovery was reported for 100% in outpatient care and 90% of hospitalized individuals. SARS-CoV-2 impacts health care of individuals with intoxication-type IMDs worldwide. Most infected individuals, however, showed mild symptoms and did not require hospitalization. SARS-CoV-2-induced metabolic decompensations were usually mild without increased risk for ICU treatment. Overall prognosis of infected individuals is very promising and IMD-specific or COVID-19-related complications have not been observed.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Maladies Rares du Développement : Génétique, Régulation et Protéomique (RADEME) - ULR 7364

Date de dépôt :

2024-06-25T21:36:51Z
2024-10-15T12:10:09Z